Neal Walker - Feb 1, 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Feb 1, 2024
Transactions value $
$0
Form type
4
Date filed
2/5/2024, 07:36 PM
Previous filing
Aug 24, 2023
Next filing
Mar 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Stock Option (Right to Buy) Award $0 +497K $0.00 497K Feb 1, 2024 Common Stock 497K $1.20 Direct F1
transaction ACRS Restricted Stock Units Award $0 +142K $0.00 142K Feb 1, 2024 Common Stock 142K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.